World's Best Scientists 2026 revealed!
Lesley Seymour

Lesley Seymour

D-Index & Metrics

Medicine

D-Index
83
Citations
43637
World Ranking
15357
National Ranking
638

Overview

Lesley Seymour is affiliated with Queen's University in Canada and has a significant body of research in the fields of Medicine and Biochemistry, Genetics and Molecular Biology. Their scholarly contributions focus prominently on oncology and pulmonary and respiratory medicine, with substantial work in cancer research and molecular biology.

The primary areas of study covered by Seymour include:

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research
  • Molecular Biology
  • Economics and Econometrics

The main topics addressed across their publications encompass:

  • Cancer Immunotherapy and Biomarkers
  • Cancer Genomics and Diagnostics
  • Lung Cancer Treatments and Mutations
  • Cancer Treatment and Pharmacology
  • Health Systems, Economic Evaluations, Quality of Life
  • Statistical Methods in Clinical Trials
  • Occupational and environmental lung diseases

Lesley Seymour's recent scientific papers include:

  • Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies, 2022, Nature Communications
  • Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022, 2022, Annals of Oncology
  • Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial, 2023, The Lancet
  • Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance, 2023, BMJ
  • IND227 phase III (P3) study of cisplatin/pemetrexed (CP) with or without pembrolizumab (pembro) in patients (pts) with malignant pleural mesothelioma (PM): A CCTG, NCIN, and IFCT trial., 2023, Journal of Clinical Oncology

Frequent co-authors collaborating with Seymour include:

  • Dongsheng Tu
  • Scott A. Laurie
  • John Hilton
  • Moira Rushton
  • Wei Tu

The most common publication venues where Seymour's work appears are:

  • Journal of Clinical Oncology
  • Cancer Research
  • Clinical Cancer Research
  • Annals of Oncology
  • Journal of Thoracic Oncology

Best Publications

  • Erlotinib in previously treated non-small-cell lung cancer.

    Frances A. Shepherd;José Rodrigues Pereira;Tudor Ciuleanu;Eng Huat Tan

  • Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group

    Jean Pierre Pignon;Hélène Tribodet;Giorgio V. Scagliotti;Jean Yves Douillard

  • iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

    Lesley Seymour;Jan Bogaerts;Andrea Perrone;Robert Ford

  • Erlotinib in lung cancer - molecular and clinical predictors of outcome.

    Ming Sound Tsao;Akira Sakurada;Jean Claude Cutz;Jean Claude Cutz;Chang Qi Zhu;Chang Qi Zhu

  • Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer

    Timothy Winton;Robert Livingston;David H Johnson;James Rigas

  • RECIST 1.1—Update and clarification: From the RECIST committee

    Lawrence H. Schwartz;Lawrence H. Schwartz;Saskia Litiere;Elisabeth G. E. de Vries;Robert Ford

  • Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study.

    Kerby Shedden;Jeremy M.G. Taylor;Steven A. Enkemann;Ming Sound Tsao

  • Role of KRAS and EGFR As Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21

    Chang Qi Zhu;Gilda Da Cunha Santos;Keyue Ding;Akira Sakurada

  • Clinical Predictive Value of the in Vitro Cell Line, Human Xenograft, and Mouse Allograft Preclinical Cancer Models

    Theodora Voskoglou-Nomikos;Joseph L. Pater;Lesley Seymour

  • Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: A systematic review and meta-analysis of individual patient data from 16 randomized controlled trials

    Sarah Burdett;S. Burdett;R. Stephens;L. Stewart

  • High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial.

    W R Bezwoda;L Seymour;R D Dansey

  • Comparison of Gemcitabine Versus the Matrix Metalloproteinase Inhibitor BAY 12-9566 in Patients With Advanced or Metastatic Adenocarcinoma of the Pancreas: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

    Malcolm J. Moore;J. Hamm;J. Dancey;P. D. Eisenberg

  • Randomized Phase III Trial of Vinorelbine Plus Cisplatin Compared With Observation in Completely Resected Stage IB and II Non–Small-Cell Lung Cancer: Updated Survival Analysis of JBR-10

    Charles A. Butts;Keyue Ding;Lesley Seymour;Philip Twumasi-Ankrah

  • Prognostic and Predictive Gene Signature for Adjuvant Chemotherapy in Resected Non–Small-Cell Lung Cancer

    Chang Qi Zhu;Keyue Ding;Dan Strumpf;Barbara A. Weir

  • Symptom Improvement in Lung Cancer Patients Treated With Erlotinib: Quality of Life Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21

    Andrea Bezjak;Dongsheng Tu;Lesley Seymour;Gary Clark

  • ERCC1 Isoform Expression and DNA Repair in Non-Small-Cell Lung Cancer

    Luc Friboulet;Ken André Olaussen;Ken André Olaussen;Jean Pierre Pignon;Frances A. Shepherd

  • Prognostic and Predictive Importance of p53 and RAS for Adjuvant Chemotherapy in Non–Small-Cell Lung Cancer

    Ming Sound Tsao;Sarit Aviel-Ronen;Keyue Ding;Davina Lau

  • Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer

    Srikala S Sridhar;Lesley Seymour;Frances A Shepherd

  • A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial

    F. A. Shepherd;J. Pereira;T. E. Ciuleanu;E. H. Tan

  • Age and Comorbidity As Independent Prognostic Factors in the Treatment of Non–Small-Cell Lung Cancer: A Review of National Cancer Institute of Canada Clinical Trials Group Trials

    Timothy R. Asmis;Keyue Ding;Lesley Seymour;Frances A. Shepherd

Frequent Co-Authors

Frances A. Shepherd
Frances A. Shepherd Princess Margaret Cancer Centre
Dongsheng Tu
Dongsheng Tu Queen's University
Ming-Sound Tsao
Ming-Sound Tsao Princess Margaret Cancer Centre
Natasha B. Leighl
Natasha B. Leighl Princess Margaret Cancer Centre
Karen A. Gelmon
Karen A. Gelmon University of British Columbia
Jean-Yves Douillard
Jean-Yves Douillard European Society for Medical Oncology
Kim N. Chi
Kim N. Chi BC Cancer Agency
Jean-Charles Soria
Jean-Charles Soria Amgen (United States)
Elizabeth A. Eisenhauer
Elizabeth A. Eisenhauer Queen's University
Elisabeth Brambilla
Elisabeth Brambilla Grenoble Alpes University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

The pathway to a career in medicine is diverse and expanding, with many related degrees and online options available. Students who want to pursue administrative or leadership positions in healthcare may consider cahme accredited online healthcare administration programs. These programs provide rigorous training in management skills and health policy, all through accredited and flexible online coursework.

For nurses seeking career advancement, online bridge programs are increasingly popular. Options like online rn to bsn programs without clinical requirements offer a streamlined path for registered nurses to earn a BSN, with no on-site clinical hours required.

If you’re interested in advanced practice nursing, there are accelerated and accessible options available. You can explore the fastest dnp online program to complete your Doctor of Nursing Practice in less time. Alternatively, you may consider one of the easiest dnp programs if you’re looking for flexible admission criteria or a more manageable workload.

These online degree pathways open doors to fulfilling roles in the healthcare field, whether in clinical practice, leadership, or administration.

Best Scientists Citing Lesley Seymour

Trending Scientists

Recently Published Articles